NanoString Technologies: establishing new UK headquarters in Amersham
NanoString Technologies (NSTG) provides tools for translational research and molecular diagnostics. Headquartered in Seattle and founded in 2003, the company began international sales operations in 2008, and in 2013 launched Prosigna™, its first in vitro diagnostic product for prognosis of early-stage breast cancer, in Europe and Israel.
In 2014, with UKTI, Buckinghamshire Business First, Thames Valley Chamber support, NanoString established a new UK headquarters in Amersham as part of the company’s continuing international expansion. Everton Robinson, Director of EMEA Sales Life Sciences, NanoString Technologies-Europe, said: “2015 will be a year of continuing revenue growth, with the aim of expanding the organisation further across the UK and Europe in 2016.
Operating from the healthcare cluster in Buckinghamshire provides the local talent and international connections we need to serve our clients and support this ambitious growth.”